Pharmacology · Disease-modifying antirheumatic agents
Biologic DMARDs
Protein-based disease-modifying antirheumatic drugs — TNF inhibitors, a B-cell-depleting antibody and a T-cell costimulation blocker — that each engage one defined extracellular target rather than acting diffusely, and that all share a tuberculosis-screening requirement before the first dose even where their other risks differ sharply.
Quick revision
One protein family (TNF inhibitors) does most of the work in this class, but the class also contains a B-cell-depleting antibody and a T-cell costimulation blocker with a different boxed-warning shape entirely — TB screening is close to universal here, but the rest of the risk profile is not.
- Every TNF inhibitor covered here carries a boxed warning for serious infection, including tuberculosis, and for lymphoma/malignancy reported in children and adolescents treated with TNF blockers. (1) (2) (3) (4)
- Hepatosplenic T-cell lymphoma has been reported specifically with infliximab and adalimumab in adolescent and young adult males with inflammatory bowel disease on concomitant azathioprine or 6-mercaptopurine — etanercept's label does not carry that same signal, and etanercept is not FDA-approved for inflammatory bowel disease at all. (2) (3) (1)
- Etanercept is a fusion protein — the soluble TNF receptor fused to an antibody Fc fragment — while infliximab, adalimumab and golimumab are true monoclonal antibodies against TNF-alpha; that structural difference is why they are not interchangeable class members. (1) (2) (3)
- Rituximab's boxed warnings are entirely different in kind from the TNF inhibitors': fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation and progressive multifocal leukoencephalopathy, with no TB-specific boxed warning at all. (5)
- Abatacept has no absolute contraindications listed in its own label, but combining it with a TNF antagonist raised serious infections from 0.8% to 4.4% in trials, which is why that combination is avoided. (6)
- Latent tuberculosis is tested for and treated before the first dose of a TNF inhibitor or abatacept, and patients are monitored for active TB throughout treatment even after a negative baseline test. (1) (2) (3) (6)
- Hepatitis B reactivation is screened for before starting any of these agents; rituximab's label requires HBsAg and anti-HBc testing in every patient before treatment. (5) (1)
- Live vaccines are avoided during treatment with this class, and abatacept's label extends that avoidance to three months after the last dose. (1) (6)
Overview
Biologic DMARDs are protein-based agents that target one extracellular molecule each, which is what separates them from the diffuse, multi-pathway action of the conventional synthetic DMARDs. The largest group by far is the TNF inhibitors — etanercept, infliximab, adalimumab and golimumab — but the class also includes rituximab, a CD20-directed antibody that depletes B lymphocytes, and abatacept, a fusion protein that blocks the T-cell costimulation signal delivered through CD28. Grouping all of these under one heading is a convenience of history and route of administration (injection or infusion) more than a statement about a shared mechanism. (7)
What genuinely is shared, across every TNF inhibitor and across abatacept, is the requirement to test for latent tuberculosis and treat it before the first dose, because these agents interfere with the immune surveillance that normally keeps latent infection contained. Patients with tuberculosis on this class have frequently presented with disseminated or extrapulmonary disease rather than the classic pulmonary pattern, which is one reason vigilance continues throughout treatment and not only at baseline. (1) (2) (3) (6)
Malignancy risk does not read the same way across the class. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers as a group. A more specific and more severe signal — hepatosplenic T-cell lymphoma — has been reported with infliximab and adalimumab, concentrated in adolescent and young adult males with Crohn's disease or ulcerative colitis who were also taking azathioprine or 6-mercaptopurine. Etanercept's own label does not carry that hepatosplenic-lymphoma language, consistent with the fact that etanercept has not been shown effective in inflammatory bowel disease and is not approved for it. Generalising the hepatosplenic-lymphoma risk to the whole TNF-inhibitor class, rather than to this specific drug-plus-thiopurine-plus-IBD picture, would overstate what the evidence actually shows. (2) (3) (1)
Rituximab and abatacept sit furthest from the TNF-inhibitor template. Rituximab's boxed warnings — fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation and progressive multifocal leukoencephalopathy — describe an entirely different hazard profile from tuberculosis reactivation, and its rheumatoid arthritis indication is reserved for patients who have already had an inadequate response to one or more TNF antagonists, used in combination with methotrexate. Abatacept, by contrast, carries no boxed warning and no absolute contraindication in its own label, but the data on combining it with a TNF antagonist — more than doubling the serious infection rate compared with TNF-antagonist therapy alone — is exactly the kind of drug-specific finding that a class-wide statement about biologic DMARD safety would miss. (5) (6)
Classification and drug examples
Divided by target and by molecular format, since "biologic DMARD" spans a fusion protein, three anti-TNF monoclonal antibodies, an anti-CD20 antibody and a T-cell costimulation blocker.
TNF-receptor fusion protein
A soluble decoy receptor rather than an antibody; binds both TNF-alpha and TNF-beta (lymphotoxin-alpha). (1)
- Etanercept (Enbrel) · Subcutaneous — A dimeric fusion protein of the p75 TNF receptor extracellular domain linked to human IgG1 Fc; the only agent in this subclass. Not approved for inflammatory bowel disease. (1)
Anti-TNF-alpha monoclonal antibodies
True monoclonal antibodies that bind soluble and, for some members, transmembrane TNF-alpha directly; broader indications than etanercept, including inflammatory bowel disease for infliximab and adalimumab. (2) (3) (4)
- Infliximab (Remicade) · Intravenous infusion — A chimeric (part-mouse, part-human) monoclonal antibody; used with methotrexate in rheumatoid arthritis and alone or with immunomodulators in Crohn's disease and ulcerative colitis. (2)
- Adalimumab (Humira) · Subcutaneous — A fully human monoclonal antibody; the broadest indication list in this subclass, extending to hidradenitis suppurativa and non-infectious uveitis. (3)
- Golimumab (Simponi, Simponi Aria) · Subcutaneous or intravenous (Simponi Aria) — A fully human monoclonal antibody against both soluble and transmembrane TNF-alpha; the intravenous form is used for ulcerative colitis. (4)
- Certolizumab pegol (Cimzia) · Subcutaneous — A PEGylated Fab' fragment against TNF-alpha, structurally distinct from the full antibodies above; shares the class TB-screening requirement. (7)
CD20-directed B-cell-depleting antibody
Removed from the TNF pathway entirely; its rheumatoid arthritis indication follows failure of TNF-antagonist therapy rather than preceding it. (5)
T-cell costimulation modulator
Blocks the second signal T cells need for full activation, rather than removing a cytokine or a cell population. (6)
- Abatacept (Orencia) · Subcutaneous or intravenous — A CTLA-4–IgG1 Fc fusion protein; carries no absolute contraindication in its own label, unusually for this class. (6)
Mechanism of action
Each biologic DMARD binds one defined extracellular target. Etanercept and the anti-TNF monoclonal antibodies neutralise TNF-alpha, though by different molecular formats; rituximab depletes CD20-positive B lymphocytes directly; abatacept blocks the CD80/CD86–CD28 costimulatory signal T cells need for full activation. There is no shared receptor or shared cell type across the whole class.
- Molecular target
- TNF-alpha and TNF-beta (etanercept); TNF-alpha (infliximab, adalimumab, golimumab, certolizumab pegol); CD20 on B lymphocytes (rituximab); CD80/CD86 on antigen-presenting cells (abatacept)
- Pharmacodynamic effect
- Immunomodulatory rather than cytotoxic to the patient's own tissue — the intended effect is suppression of pathological immune signalling, not cell killing outside the rituximab-targeted B-cell population
- Effect kinetics
- Onset over weeks; effect is sustained only while dosing continues and, for rituximab, while B-cell depletion persists
Etanercept intercepts TNF before it reaches its receptor
As a dimeric fusion protein of the p75 TNF receptor's extracellular domain linked to IgG1 Fc, etanercept binds circulating TNF-alpha and TNF-beta (lymphotoxin-alpha), inhibiting their binding to cell-surface TNF receptors and rendering TNF biologically inactive. (1)
Infliximab, adalimumab and golimumab bind TNF-alpha directly as antibodies
Infliximab is a chimeric monoclonal antibody, adalimumab a fully human recombinant IgG1 monoclonal antibody, and golimumab a human monoclonal antibody; all bind TNF-alpha and block its interaction with cell-surface TNF receptors, though their chemistry, immunogenicity and half-life differ. (2) (3) (4)
TNF blockade removes a central pro-inflammatory signal
TNF-alpha drives synovial inflammation, cartilage and bone destruction in rheumatoid arthritis; neutralising it reduces downstream cytokine cascades, cellular infiltration and the acute-phase response. (7)
Rituximab depletes B lymphocytes by binding CD20
As a CD20-directed cytolytic antibody, rituximab targets B lymphocytes for destruction; because CD20 is not expressed on stem cells or plasma cells, B-cell repopulation eventually occurs, but the depletion interval is what produces the drug's effect in rheumatoid arthritis and certain lymphomas. (5)
Abatacept blocks T-cell costimulation rather than a cytokine
As a soluble fusion protein of the CTLA-4 extracellular domain linked to a modified human IgG1 Fc, abatacept binds CD80 and CD86 on antigen-presenting cells, blocking their interaction with CD28 on T cells and so blocking the second signal required for full T-lymphocyte activation; in vitro this decreases T-cell proliferation and production of TNF-alpha, interferon-gamma and interleukin-2. (6)
Major clinical uses
Read each row as drug → indication → role in therapy. Treatment is always directed by the treating clinician.
| Drug | Indication | Role | Note |
|---|---|---|---|
| Etanercept | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis in adults; polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis from age 2 | first-line biologic option | Not approved for Crohn's disease or ulcerative colitis, unlike infliximab and adalimumab. (1) |
| Infliximab | Rheumatoid arthritis (with methotrexate), Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis | first-line biologic option | Given by intravenous infusion, which is the practical reason it is chosen over a self-injected TNF inhibitor in some settings. (2) |
| Adalimumab | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, non-infectious uveitis | first-line biologic option | The broadest indication list among the TNF inhibitors covered here. (3) |
| Golimumab | Rheumatoid arthritis (with methotrexate), psoriatic arthritis, ankylosing spondylitis, moderately to severely active ulcerative colitis | first-line biologic option | Subcutaneous Simponi and intravenous Simponi Aria are different formulations of the same molecule with different indication emphasis. (4) |
| Rituximab | Moderately to severely active rheumatoid arthritis, in combination with methotrexate | reserved, after inadequate response to one or more TNF antagonists | Its RA indication is written for exactly the patients whom the TNF inhibitors above have already failed. (5) |
| Abatacept | Adult rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and acute graft-versus-host disease prophylaxis with a calcineurin inhibitor and methotrexate | option after inadequate response to a conventional DMARD | Concurrent use with a TNF antagonist or another biologic is specifically discouraged because of the added infection risk documented in trials. (6) |
Pharmacokinetics
| Drug | Route | Absorption | Metabolism | Elimination | Half-life | Adjust in |
|---|---|---|---|---|---|---|
| Etanercept | Subcutaneous injection | Not orally bioavailable; a protein given parenterally | Catabolised as a protein rather than by hepatic enzymes | Proteolytic degradation | — | See prescribing reference (1) |
| Infliximab | Intravenous infusion | Not applicable (parenteral) | Catabolised as a protein | Proteolytic degradation, with immunogenicity (anti-drug antibodies) reducing effective exposure in some patients | — | See prescribing reference (2) |
| Rituximab | Intravenous infusion | Not applicable (parenteral) | Catabolised as a protein | Proteolytic degradation, alongside B-cell depletion whose duration outlasts measurable drug levels | — | See prescribing reference (5) |
- This page gives no dose regimens by design. Dosing, infusion protocols and monitoring intervals depend on indication, weight, prior therapy and response, and belong in a current prescribing reference used by the treating clinician.
- As proteins, none of these drugs is given orally, none is meaningfully metabolised by cytochrome P450 enzymes, and drug-drug interaction patterns look nothing like those of the small-molecule conventional DMARDs or JAK inhibitors. (1) (2) (5)
- Immunogenicity — the patient's own immune system forming antibodies against the biologic — is a recognised reason for loss of response over time, most documented for the chimeric antibody infliximab, and is part of why concomitant methotrexate is often used alongside a TNF inhibitor. (2)
Adverse effects
Common
- Injection site or infusion reactions: Etanercept injection-site reactions occurred in 37% of treated patients against 11% on placebo. Infliximab infusion reactions and delayed hypersensitivity are recognised risks, particularly on re-administration. (1) (2)
- Upper respiratory infection: Reported across the TNF inhibitors: 38% with etanercept versus 30% on placebo; 32% with infliximab among patients receiving four or more infusions; 17% with adalimumab versus 13% on placebo; 16% with golimumab versus 13% on placebo. (1) (2) (3) (4)
- Headache: Reported with abatacept (18% versus 13% on placebo) and infliximab (18%). (6) (2)
Serious adverse effects
- Serious infection, including tuberculosis: Every TNF inhibitor and abatacept carries this risk; patients with tuberculosis on this class have frequently presented with disseminated or extrapulmonary disease rather than typical pulmonary TB. Most patients who developed serious infection on a TNF inhibitor were also taking concomitant immunosuppressants such as methotrexate or corticosteroids. Latent TB is tested for and treated before the first dose, and patients are monitored for active TB throughout treatment; new fever, cough or other infective symptoms during treatment are reported to the treating clinician promptly. (1) (2) (3) (4) (6)
- Lymphoma and other malignancy in children and adolescents: Reported with TNF blockers as a class, including etanercept, infliximab, adalimumab and golimumab. This risk is disclosed and weighed against disease severity by the treating clinician, particularly in paediatric prescribing. (1) (2) (3) (4)
- Hepatosplenic T-cell lymphoma: A rare, usually fatal malignancy reported specifically with infliximab and adalimumab, concentrated in adolescent and young adult males with inflammatory bowel disease taking concomitant azathioprine or 6-mercaptopurine. Etanercept's label does not carry this specific signal. The specific IBD-plus-thiopurine-plus-anti-TNF-antibody combination is a documented clinical consideration the treating clinician weighs, not a reason to generalise the risk to every TNF inhibitor. (2) (3)
- Hepatitis B reactivation: Can occur with TNF inhibitors and with rituximab in chronic HBV carriers, sometimes resulting in fulminant hepatitis and death with rituximab. HBV status is tested before treatment across this class; rituximab's label specifically requires HBsAg and anti-HBc testing in every patient. (1) (2) (5)
- Demyelinating disease: Transverse myelitis, optic neuritis, multiple sclerosis and Guillain-Barre syndrome have been reported with TNF inhibitors. Caution is used in patients with pre-existing demyelinating disorders, and new neurological symptoms during treatment are reported promptly. (1) (2)
- New or worsening heart failure: Reported, rarely, with TNF inhibitors including in patients with no known pre-existing cardiovascular disease. Caution in patients with heart failure, and infliximab doses above 5 mg/kg are avoided in moderate to severe heart failure. (1) (2)
- Fatal infusion-related reactions: Deaths within 24 hours of rituximab infusion have occurred; approximately 80% of fatal infusion reactions occurred with the first infusion. Infusions are monitored clinically and stopped for severe reactions; this is a reason rituximab infusion is never a self-administered or unsupervised event. (5)
- Progressive multifocal leukoencephalopathy: JC virus infection resulting in PML and death can occur with rituximab; most cases in autoimmune disease had prior or concurrent immunosuppressive therapy, and most were diagnosed within 12 months of the last infusion. New-onset neurological symptoms during or after rituximab treatment are evaluated urgently, including neurology consultation, brain MRI and lumbar puncture as directed by the treating team. (5)
- Elevated infection risk with TNF-antagonist/abatacept combination: Concomitant intravenous abatacept and a TNF antagonist produced more infections (63% versus 43%) and more serious infections (4.4% versus 0.8%) than TNF-antagonist monotherapy in trials. This combination is avoided; abatacept is not used alongside a TNF antagonist or another biologic DMARD. (6)
Drug-specific effects
- Etanercept: Rare pancytopenia and very rare aplastic anaemia, some fatal, have been reported; contraindicated in sepsis specifically. (1)
- Infliximab and adalimumab: Serum sickness-like reactions can occur on re-administration after a treatment gap, and both can produce autoantibodies with a lupus-like syndrome. (2) (3)
- Rituximab: Tumour lysis syndrome risk in patients with a high circulating malignant cell count, and severe mucocutaneous reactions, some fatal, are a separate boxed warning. (5)
- Abatacept: Patients with chronic obstructive pulmonary disease had a markedly higher rate of respiratory adverse events (27% versus 6% on placebo); fatal anaphylaxis has been reported post-marketing, and angioedema can have delayed onset even after several doses. (6)
Contraindications, precautions and interactions
Contraindications
- Etanercept: sepsis. (1)
- Infliximab: doses above 5 mg/kg in moderate or severe heart failure; previous severe hypersensitivity reaction to infliximab or to murine proteins. (2)
- Adalimumab, golimumab and abatacept carry no absolute contraindications in their own labelling. (3) (4) (6)
Precautions
- Active infection of any kind is a reason to defer or interrupt treatment with any member of this class until it is controlled. (1) (2) (3) (4)
- Pre-existing demyelinating disease is a reason for caution with TNF inhibitors specifically. (1) (2)
- Heart failure is a reason for caution across the TNF inhibitors, with a specific dose ceiling for infliximab in moderate to severe disease. (1) (2)
- COPD is a reason for closer monitoring with abatacept specifically, given the markedly higher respiratory adverse event rate observed in that population. (6)
- Live vaccines are avoided during treatment with this class; abatacept's label extends that avoidance to three months after the last dose. (1) (6)
Drug interactions
- TNF antagonist plus abatacept: More than doubles serious infection risk compared with TNF-antagonist monotherapy and is not recommended. (6)
- Two biologic DMARDs together, or a biologic with a JAK inhibitor: Not recommended because of added infection risk without a matching efficacy benefit. (7)
- Azathioprine or 6-mercaptopurine with infliximab or adalimumab: The combination most associated with reported cases of hepatosplenic T-cell lymphoma, concentrated in adolescent and young adult males with inflammatory bowel disease. (2) (3)
Comparison tables
TB screening is close to universal in this class; the rest of the safety picture is drug-specific. Choice of agent belongs to the treating clinician.
| Drug | Molecular target/format | Boxed-warning theme | Distinguishing safety point |
|---|---|---|---|
| Etanercept | TNF-alpha/beta, fusion protein | Serious infection incl. TB; paediatric malignancy | Contraindicated in sepsis; no hepatosplenic-lymphoma signal; not used in IBD (1) |
| Infliximab | TNF-alpha, chimeric antibody | Serious infection incl. TB; malignancy incl. hepatosplenic T-cell lymphoma | Heart-failure dose ceiling; infusion/serum-sickness reactions on re-dosing (2) |
| Adalimumab | TNF-alpha, fully human antibody | Serious infection incl. TB; malignancy incl. hepatosplenic T-cell lymphoma | Broadest indication list of the TNF inhibitors here (3) |
| Golimumab | TNF-alpha, fully human antibody | Serious infection incl. TB; paediatric malignancy | Subcutaneous and intravenous forms with different indication emphasis (4) |
| Rituximab | CD20 on B lymphocytes | Fatal infusion reactions; mucocutaneous reactions; HBV reactivation; PML | No TB-specific boxed warning; reserved for TNF-inhibitor failure (5) |
| Abatacept | CD80/CD86, blocking CD28 costimulation | None — no boxed warning in its own label | No absolute contraindication; markedly higher infection risk when combined with a TNF antagonist (6) |
High-yield exam pearls
- Etanercept is a receptor fusion protein; infliximab, adalimumab and golimumab are true monoclonal antibodies. (1) (2) (3) That structural difference is why etanercept lacks efficacy in inflammatory bowel disease while infliximab and adalimumab are approved for it.
- Hepatosplenic T-cell lymphoma is a drug-plus-population-specific finding, not a whole-class TNF-inhibitor property. (2) (3) (1) It is reported with infliximab and adalimumab in adolescent/young adult males with IBD on concomitant azathioprine or 6-mercaptopurine; etanercept's label does not carry the same language.
- Rituximab's boxed warnings have nothing to do with tuberculosis. (5) They are fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation and PML — a completely different hazard shape from the TNF inhibitors.
- Abatacept plus a TNF antagonist is a combination to avoid, not a way to double the benefit. (6) Trials showed serious infections rising from 0.8% to 4.4% with the combination compared with TNF-antagonist monotherapy.
- TB screening in this class is close to universal but not the same everywhere. (1) (6) (5) Every TNF inhibitor and abatacept require it before the first dose; rituximab's screening focus is hepatitis B rather than TB.
- Rituximab in rheumatoid arthritis is a second-line biologic, not a first choice. (5) Its label indication follows inadequate response to one or more TNF antagonists, used with methotrexate.
Common exam traps
- Trap: Assuming every biologic DMARD carries the same boxed warning about tuberculosis. Actually: The TNF inhibitors do. Abatacept requires the same mandatory TB screening before treatment but carries no boxed warning at all in its own label — the requirement sits under Warnings and Precautions instead. Rituximab's boxed warnings are infusion reactions, mucocutaneous reactions, hepatitis B reactivation and PML, with no TB-specific language of any kind. (1) (6) (5)
- Trap: Generalising hepatosplenic T-cell lymphoma to "all TNF inhibitors." Actually: It is specifically reported with infliximab and adalimumab in adolescent/young adult males with IBD on concomitant thiopurine therapy; etanercept's own label does not carry this signal, and etanercept is not approved for IBD. (2) (3) (1)
- Trap: Believing biologics can safely be stacked for extra efficacy. Actually: Combining a TNF antagonist with abatacept, or combining two biologics, or a biologic with a JAK inhibitor, raises infection risk substantially without a matching efficacy gain and is not recommended. (6) (7)
- Trap: Treating etanercept as interchangeable with infliximab or adalimumab because all three are "TNF inhibitors." Actually: Etanercept is a fusion protein, not an antibody, is contraindicated specifically in sepsis, and lacks IBD efficacy that infliximab and adalimumab both have. (1) (2) (3)
- Trap: Assuming abatacept, having no boxed warning, is risk-free. Actually: It still carries a mandatory TB-screening requirement, a markedly higher COPD respiratory adverse event rate, rare fatal anaphylaxis, and a serious-infection risk that more than doubles when combined with a TNF antagonist. (6)
Self-test questions
Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.
Structurally, what distinguishes etanercept from infliximab, adalimumab and golimumab?
- Etanercept is a small molecule, the others are antibodies
- Etanercept is a soluble TNF-receptor fusion protein, the others are monoclonal antibodies against TNF-alpha
- All four are chemically identical monoclonal antibodies
- Etanercept is the only one given intravenously
Show answer
Answer: Etanercept is a soluble TNF-receptor fusion protein, the others are monoclonal antibodies against TNF-alpha
Etanercept is a dimeric fusion protein of the p75 TNF receptor's extracellular domain linked to IgG1 Fc, binding TNF-alpha and TNF-beta as a decoy receptor, whereas infliximab, adalimumab and golimumab are true monoclonal antibodies against TNF-alpha. (1) (2) (3) (4)
Hepatosplenic T-cell lymphoma has been reported most specifically with which combination?
- Etanercept alone in rheumatoid arthritis
- Infliximab or adalimumab plus azathioprine/6-mercaptopurine in adolescent/young adult male IBD patients
- Abatacept in elderly patients with COPD
- Rituximab in first-line rheumatoid arthritis
Show answer
Answer: Infliximab or adalimumab plus azathioprine/6-mercaptopurine in adolescent/young adult male IBD patients
The signal is concentrated in infliximab- or adalimumab-treated adolescent and young adult males with Crohn's disease or ulcerative colitis who were also taking a thiopurine; etanercept's label does not carry the same language. (2) (3)
Which set of boxed warnings belongs to rituximab rather than to the TNF inhibitors?
- Serious infection including tuberculosis, and paediatric malignancy
- Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy
- Embryofetal toxicity and hepatotoxicity
- Major adverse cardiovascular events and thrombosis
Show answer
Answer: Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy
Rituximab's boxed warnings are infusion-reaction, mucocutaneous-reaction, HBV-reactivation and PML risks — a distinct hazard profile from the TB/malignancy warning shared by the TNF inhibitors. (5)
What happened in trials when abatacept was combined with a TNF antagonist?
- Serious infections fell compared with TNF-antagonist monotherapy
- Serious infections rose from 0.8% to 4.4% compared with TNF-antagonist monotherapy
- No difference in infection rates was observed
- The combination improved efficacy with no added risk
Show answer
Answer: Serious infections rose from 0.8% to 4.4% compared with TNF-antagonist monotherapy
Concomitant intravenous abatacept and a TNF antagonist produced more infections (63% vs 43%) and more serious infections (4.4% vs 0.8%) than TNF-antagonist monotherapy, which is why the combination is not recommended. (6)
A patient is being considered for rituximab for rheumatoid arthritis. What does its FDA label require to have already happened?
- Nothing — rituximab is first-line therapy
- An inadequate response to one or more TNF antagonist therapies, with rituximab then used in combination with methotrexate
- Prior treatment with abatacept specifically
- A positive tuberculosis test
Show answer
Answer: An inadequate response to one or more TNF antagonist therapies, with rituximab then used in combination with methotrexate
Rituximab's RA indication is written for patients with moderately to severely active disease and an inadequate response to one or more TNF antagonists, used in combination with methotrexate. (5)
Which biologic DMARD in this class is the only one with no absolute contraindication listed in its own FDA label?
- Etanercept
- Infliximab
- Abatacept
- Rituximab
Why is tuberculosis screening required before starting a TNF inhibitor or abatacept?
- Because these drugs are directly toxic to Mycobacterium tuberculosis
- Because they interfere with immune surveillance that normally contains latent TB, and patients on this class have frequently presented with disseminated or extrapulmonary disease
- Because TB screening is only a billing requirement with no clinical basis
- Because TNF inhibitors cure latent TB on their own
Show answer
Answer: Because they interfere with immune surveillance that normally contains latent TB, and patients on this class have frequently presented with disseminated or extrapulmonary disease
TNF and T-cell costimulation are part of the immune response that contains latent tuberculosis; blocking them allows reactivation, and patients affected have frequently presented atypically with disseminated or extrapulmonary disease. (1) (6)
Frequently asked questions
Are all TNF inhibitors basically the same drug with different names?
No. Etanercept is a fusion protein rather than a true antibody and is not effective in inflammatory bowel disease, while infliximab, adalimumab and golimumab are monoclonal antibodies with broader indication lists that include Crohn's disease or ulcerative colitis for some members. Their boxed-warning themes overlap heavily (infection, TB, paediatric malignancy) but the specific hepatosplenic-lymphoma signal is concentrated in infliximab and adalimumab, not etanercept. (1) (2) (3)
Why does rituximab need a different screening test than the TNF inhibitors?
Rituximab's boxed warnings centre on infusion reactions, severe skin reactions, hepatitis B reactivation and PML rather than tuberculosis, so its label specifically requires HBsAg and anti-HBc testing in every patient before treatment, distinct from the TB-screening focus that governs the TNF inhibitors and abatacept. (5)
Can two biologic DMARDs be combined for a stronger effect?
This is specifically discouraged. Trial data with abatacept plus a TNF antagonist showed serious infections rising from 0.8% to 4.4% compared with TNF-antagonist monotherapy, and combining two biologics or a biologic with a JAK inhibitor carries the same kind of added infection risk without a matching efficacy benefit. (6) (7)
Why is rituximab reserved for patients who have already tried a TNF inhibitor?
Its FDA rheumatoid arthritis indication is written specifically for moderately to severely active disease with an inadequate response to one or more TNF antagonist therapies, used together with methotrexate — it is a second-line biologic by label, not a first choice. (5)
Is hepatosplenic T-cell lymphoma a risk with every TNF inhibitor?
The documented signal is specific to infliximab and adalimumab, concentrated in adolescent and young adult males with inflammatory bowel disease who were also taking azathioprine or 6-mercaptopurine. Etanercept's own label does not carry this language, which is consistent with etanercept not being approved for inflammatory bowel disease at all. (2) (3) (1)
References
- ENBREL (etanercept) — prescribing information DailyMed, U.S. National Library of Medicine
- REMICADE (infliximab) — prescribing information DailyMed, U.S. National Library of Medicine
- HUMIRA (adalimumab) — prescribing information DailyMed, U.S. National Library of Medicine
- SIMPONI (golimumab) — prescribing information DailyMed, U.S. National Library of Medicine
- RITUXAN (rituximab) — prescribing information DailyMed, U.S. National Library of Medicine
- ORENCIA (abatacept) — prescribing information DailyMed, U.S. National Library of Medicine
- Disease-Modifying Antirheumatic Drugs (DMARDs) StatPearls Publishing / NCBI Bookshelf, 2025